Vinorelbine for non-small cell lung cancer

Expert Opinion on Drug Safety

Volumn 9, Issue 3, 2010, Pages 493-510

  Piccirillo, Maria Carmela ^a   Daniele, Gennaro ^a   Di Maio, Massimo ^a   Bryce, Jane ^a   De Feo, Gianfranco ^a   Del Giudice, Antonia ^a   Perrone, Francesco ^a   Morabito, Alessandro ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

NSCLC; Platinum combinations; Safety; Third generation drugs; Vinorelbine

Indexed keywords

ADENOSINE TRIPHOSPHATASE; BEVACIZUMAB; CALMODULIN DEPENDENT CALCIUM TRANSPORT ADENOSINE TRIPHOSPHATASE; CARBOPLATIN; CATHARANTHINE; CETUXIMAB; CISPLATIN; CYCLIC AMP; DOCETAXEL; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; UNCLASSIFIED DRUG; VINDESINE;

AGING; ALOPECIA; AMINO ACID METABOLISM; ANEMIA; ANOREXIA; ASTHENIA; BIOEQUIVALENCE; BLEEDING; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; CELL RESPIRATION; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG ACTIVITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FATALITY; DRUG MECHANISM; DRUG RECHALLENGE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEVER; GAIT DISORDER; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GLUTATHIONE METABOLISM; HEART ARRHYTHMIA; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; HYPOTENSION; INFECTION; INJECTION SITE REACTION; INTERSTITIAL PNEUMONIA; LEUKOPENIA; LIPOGENESIS; LIVER TOXICITY; LUNG DISEASE; LUNG EDEMA; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MITOSIS INHIBITION; MITOSIS SPINDLE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NEUTROPHIL COUNT; NUCLEIC ACID SYNTHESIS; OVERALL SURVIVAL; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PHLEBITIS; POSTMARKETING SURVEILLANCE; QUALITY OF LIFE; REVIEW; STOMATITIS; TACHYCARDIA; THROMBOCYTOPENIA; VOMITING; WEAKNESS;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; HUMANS; LUNG NEOPLASMS; RADIATION-SENSITIZING AGENTS; VINBLASTINE;

EID: 77951637766     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740331003774078     Document Type: Review

References (100)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin 2009;59:225-249
2. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899-909
3. Azzoli CG, Baker S Jr, Temin S, et al. American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J Clin Oncol 2009. [Epub ahead of print]
4. Jordan MA, Thrower D, Wilson L. Mechanism of inhibition of cell proliferation by vinca alkaloids. Cancer Res 1991;51:2212-2222
5. Potier P. The synthesis of Navelbine prototype of a new series of vinblastine derivatives. Semin Oncol 1989;16:2-4
6. Binet S, Fellous A, Lataste H, et al. In situ analysis of the action of Navelbine on various types of microtubules using immunofluorescence. Semin Oncol 1989;16(2 Suppl 4):5-8
7. Marty M, Fumoleau P, Adenis A, et al. Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol 2001;12:1643-1649
8. Leveque D, Jehl F, Quoix E, Breillout F. Clinical pharmacokinetics of vinorelbine alone and combined with cisplatin. J Clin Pharmacol 1992;32:1096-1098
9. Sorio R, Robieux I, Galligioni E, et al. Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer. Eur J Cancer 1997;33:301-303
10. Mathé G, Reizenstein P. Phase I pharmacologic study of a new Vinca alkaloid: navelbine. Cancer Lett 1985;27:285-293
11. Khayat D, Covelli A, Variol P, et al. Phase I and pharmacologic study of intravenous (IV) vinorelbine in patients with solid tumours. Proc Am Soc Clin Oncol 1995;14:abstract 1518
12. Rahmani R, Bruno R, Iliadis A, et al. Clinical pharmacokinetics of the antitumor drug navelbine (5¢-noranhydrovinbastine). Cancer Res 1987;47:5796-5799
13. Kajita J, Kuwabara T, Kobayashi H, et al. CYP3A4 is mainly responsible for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes. Drug Metab Dispos 2000;28:1121-1127
14. Jehl F, Quoix E, Leveque D, et al. Pharmacokinetic and preliminary metabolic fate of navelbine in humans as determined by high performance liquid chromatography. Cancer Res 1991;51:2073-2076
15. Leveque D, Jehl F. Clinical pharmacokinetics of vinorelbine. Clin Pharmacokinet 1996;31:184-197
16. Depierre A, Lemarie E, Dabouis G, et al. A phase II study of Navelbine (vinorelbine) in the treatment of non-small-cell lung cancer. Am J Clin Oncol 1991;14:115-119
17. Furuse K, Kubota K, Kawahara M, et al. A phase II study of vinorelbine, a new derivative of vinca alkaloid, for previously untreated advanced non-small cell lung cancer. Japan Vinorelbine Lung Cancer Study Group. Lung Cancer 1994;11:385-391
18. Crawford J, O'Rourke M, Schiller JH, et al. Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer [published erratum appears in J Clin Oncol 1996 Dec;14(12):3175]. J Clin Oncol 1996;14:2774-2784
19. Furuse K, Fukuoka M, Kuba M, et al. Randomized study of vinorelbine (VRB) versus vindesine (VDS) in previously untreated stage IIIB or IV non-small-cell lung cancer (NSCLC). Ann Oncol 1996;7:815-820
20. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1999;91:66-72
21. Vokes EE, Rosemberg RK, Jahanezeb M, et al. Multicenter phase II study of weekly oral vinorelbine for stage IV non small cell lung cancer. J Clin Oncol 1995;13:637-644
22. Depierre A, Freyer G, Jassem J, et al. Oral vinorelbine: feasibility and safety profile. Ann Oncol 2001;21:1677-1681
23. Rossi D, Catalano V, Alessandroni P, et al. A phase II study of single-agent oral vinorelbine in patients with pretreated advanced non-small-cell lung cancer. Clin Lung Cancer 2007;8:382-385
24. Jassem J, Ramlau R, Karnicka-Mlodkowska H, et al. A multicenter randomized phase II study of oral vs intravenous vinorelbine in advanced non-small-cell lung cancer patients. Ann Oncol 2001;12:1375-1381
25. Hirsh V, Desjardins P, Needles BM, et al. Oral Versus Intravenous Administration of Vinorelbine as a Single Agent for the First-Line Treatment of Metastatic Nonsmall Cell Lung Carcinoma (NSCLC): a Randomized Phase II Trial. Am J Clin Oncol 2007;30:245-251
26. Gridelli C, Manegold C, Mali P, et al. Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trial. Eur J Cancer 2004;40:2424-2431
27. Kanard A, Jatoi A, Castillo R, et al. Oral vinorelbine for the treatment of metastatic non-small cell lung cancer in elderly patients: a phase II trial of efficacy and toxicity. Lung Cancer 2004;43:345-353
28. Depierre A, Chastang C, Quoix E, et al. Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial. Ann Oncol 1994;5:37-42
29. Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994;12:360-367
30. Wozniak AJ, Crowley JJ, Balcerzak SP, et al. Randomized trial comparing cisplatin with cisaplatin plus vinorelbine in the treatment of advanced non small cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1995;16:2459-2465
31. Kelly K, Crowley J, Bunn PA, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non small cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001;19:3210-3218
32. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based dublets i advanced non small cell lung cancer. J Clin Oncol 2002;20:4285-4291
33. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non small cell lung cancer: the TAX 326 study group. J Clin Oncol 2003;21:3016-3024
34. Martoni A, Marino A, Sperandi F, et al. Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non small cell lung cancer. Eur J Cancer 2005;41:81-92
35. Georgoulias V, Ardavanis A, Tsiafaki X, et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non small cell lung cancer: a phase III randomized trial. J Clin Oncol 2005;23:2937-2945
36. Pujol JL, Breton JL, Gervais R, et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non small cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol 2005;16:602-610
37. Ohe Y, Ohashi Y, Kubuota K, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorebine foe advanced non small cell lung cancer: a four-arm cooperative study in Japan. Ann Oncol 2007;18:317-323
38. Ramsey SD, Moinpour CM, Lovato LC, et al. Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer. J Natl Cancer Inst 2002;94:291-297
39. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III Randomized Trial. J Natl Cancer Inst 2003;95:362-372
40. Gridelli C, Gallo C, Shepherd FA, et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a Phase III Trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003;21:3025-3034
41. Azim, Elattar, Loberiza, et al. Third generation triplet cytotoxic chemotherapy in advanced non-small cell lung cancer: a systematic overview. Lung Cancer 2009;64:194-198
42. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899-909
43. Stewart LA, Burdett S, Tierney JF, et al. Surgery and adjuvant chemotherapy (CT) compared to surgery alone in non-small cell lung cancer (NSCLC): a meta-analysis using individual patient data (IPD) from randomized clinical trials (RCT). J Clin Oncol 2007;25(18S):, abstract 7552
44. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs observation in resected non small cell lung cancer. N Engl J Med 2005;352:2589-2597
45. Butts CA, Ding K, Seymour L, et al. Randomized Phase III Trial of Vinorelbine Plus Cisplatin Compared With Observation in Completely Resected Stage IB and II Non-Small-Cell Lung Cancer: Updated Survival Analysis of JBR-10. J Clin Oncol 2009. [Epub ahead of print]
46. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non small cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006;7:719-727
47. Burdett SS, Stewart LA, Rydzewska L. Chemotherapy and surgery versus surgery alone in non-small cell lung cancer. Cochrane Database Syst Rev 2007;(3):CD006157
48. Gilligan D, Nicolson M, Smith I, et al. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review. Lancet 2007;369:1929-1937
49. Gottfried M, Ramlau R, Krzakowski M, et al. Cisplatin-based three drugs combination (NIP) as induction and adjuvant treatment in locally advanced non-small cell lung cancer: final results. J Thoracc Oncol 2008;3:152-157
50. Edelstein MP, Wolfe LA III, Duch DS. Potentiation of radiation therapy by vinorelbine (Navelbine) in non-small cell lung cancer. Semin Oncol 1996;23(2 Suppl 5):41-47
51. Gridelli C, Guida C, Barletta E, et al. Thoracic radiotherapy and daily vinorelbine as radiosensitizer in locally advanced non small cell lung cancer: a phase I study. Lung Cancer 2000;29:131-137 (Pubitemid 30645822)
52. Baldini E, Silvano G, Tibaldi C, et al. Sequential chemoradiation therapy with vinorelbine, ifosfamide, and cisplatin in stage IIIB non-small cell lung cancer: a phase II study. Semin Oncol 2000;27(1 Suppl 1):28-32
53. Viallet J, Brassard MA, Souhami L, et al. A phase I/II trial of neoadjuvant chemotherapy with cisplatin and vinorelbine followed by accelerated irradiation for patients with inoperable nonsmall cell lung carcinoma. Cancer. 1999;85(12):2562-2569
54. Felip E, Del Campo JM, Bodi R, et al. Cisplatin and vinorelbine followed by radiotherapy in the treatment of stage III-B non-small-cell lung cancer patients. Am J Clin Oncol 1997;20(4):404-406
55. Hirose T, Mizutani Y, Ohmori T, et al. The combination of cisplatin and vinorelbine with concurrent thoracic radiation therapy for locally advanced stage IIIA or IIIB non small cell lung cancer. Cancer Chemother Pharmacol 2006;58:361-367
56. Naito Y, Kubota K, Nihei K, et al. Concurrent chemioradiotherapy with cisplatin and vinorelbine for stage III non smal cell lung cancer. J Thoracic Oncol 2008;3:617-622
57. Kusumoto S, Hirose T, Fukayama M, et al. Induction chemoradiotherapy followed by surgery for locally advanced non-small cell lung cancer. Oncol Rep 2009;22:1157-1162
58. Winterhalder R, Deschler-Marini S, Landmann C, et al. Vinorelbine plus low-dose cisplatinum with concomitant radiotherapy for the treatment of locally advanced or inoperable non-metastasized non-small-cell lung cancer (stage I-IIIB): a phase II study. Radiother Oncol 2004;73(3):321-324
59. Krzakowski M, Provencio M, Utracka-Hutka B, et al. Oral vinorelbine and cisplatin as induction chemotherapy and concomitant chemo-radiotherapy in stage III non-small cell lung cancer: Final Results of an International Phase II Trial. J Thoracic Oncol 2008;3:994-1002
60. Leong SS, Fong KW, Lim WT, et al. A phase II trial of induction gemcitabine and vinorelbine followed by concurrent vinorelbine and radiotherapy in locally advanced non-small cell lung cancer. Lung Cancer. 2010;67(3):325-329
61. Masters GA, Haraf DJ, Hoffman PC, et al. Phase I study of vinorelbine, cisplatin, and concomitant thoracic radiation in the treatment of advanced chest malignancies. J Clin Oncol 2002;20:4191-4198
62. Vokes EE, Herndon JE II, Crawford J, et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: Cancer and Leukemia Group B Study 9431. J Clin Oncol 1998;16:2157-2163
63. Zatloukal P, Petruzelka L, Zemanova M, et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 2004;46:87-98
64. Colleoni M, Gaion F, Nelli P, et al. Weekly vinorelbine in elderly patients with non-small-cell lung cancer. Tumori 1994;80:448-452
65. Tononi A, Panzini I, Oliverio G, et al. Vinorelbine chemotherapy in non small cell lung cancer: experience in elderly patients. J Chemother 1997;9:304-308
66. Veronesi A, Crivellari D, Magri MD, et al. Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients. Eur J Cancer 1996;32:1809-1811 (Pubitemid 26306897)
67. Gridelli C, Perrone F, Gallo C, et al. Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study. Eur J cancer 1997;33:392-397
68. Buccheri G, Ferrigno D. Vinorelbine in elderly patients with inoperable non small cell lung carcinoma. Cancer 2000;88:2677-2685
69. Carrato A, Rosell R, Camps C, et al. Modified weekly regimen with vinorelbine as a single agent in unresectable non-small cell lung cancer. Lung Cancer 1997;17:261-269
70. Gebbia V, Galetta D, Lorusso V, et al. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. Lung Cancer 2008;61:369-377
71. Rittenberg CN, Gralla RJ, Rehmeyer TA. Assessing and managing venous irritation associated with vinorelbine tartrate. Oncol Nurs Forum 1995;22:707-710
72. Yoh K, Niho S, Goto K, et al. Randomized trial of drip infusion versus bolus injection of vinorelbine for the control of local venous toxicity. Lung Cancer 2007;55:337-341
73. Yoh K, Niho S, Goto K, et al. High body mass index correlates with increased risk of venous irritation by vinorelbine infusion. Jpn J Clin Oncol 2004;34:206-209
74. Hohneker JA. Safety Data From North American Trials of Vinorelbine. Onocology 1997;11(Suppl 12):16-19
75. Lapeyre-Mestre M, Gregoire N, Bugat R, et al. Vinorelbine-relate cardiac events: a meta-analysis of randomized clinical trials. Fundam Clin Pharmacol 2004;18:97-105
76. Jensen LH, Osterlind K, Rytter C, et al. Randomized cross-over study of patient preference for oral or intravenous vinorelbine in combination with carboplatin in the treatment of advanced NSCLC. Lung Cancer 2008;62:85-91
77. Tan EH, Rolski J, Grodzki T, et al. Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol 2009;20:1249-1256
78. Pace A, Bove L, Nisticò C, et al. Vinorelbine neurotoxicity: clinical and neurophysiological findings in 23 patients. J Neurol Neurosurg Psychiatry 1996;61:409-411
79. Krminsky N, Merimsky O, Kovner F, et al. Vinorelbine-related acute cardiopulmonary toxicity. Cancer Chemother Pharmacol 1999;43:180-182
80. Bergeron A, Raffy O, Vannetzel JM. Myocardial ischemia and infarction associated with vinorelbine. J Clin Oncol 1995;13:531-532
81. Tanvetyanon T, Garrity ER, Albain KS. Acute lung injury associated with vinorelbine. J Clin Oncol 2006;24:1952-1953
82. Vats M, Gupta RC, Khandelwal DV, et al. Vinorelbine induced interstitial pneumonitis: a case report. Chest 2005;128(Suppl 4):447S-8S
83. Ries LAG, Eisner M, Kosary C, et al. SEER Cancer Statistic review 1975-2000. National Cancer Institute: Bethesda, MD. 2005. Last access April 2009
84. Balducci L. Geriatric oncology: challenges for the new century. Eur J Cancer 2000;36:1741-1754
85. Fossella F, Belani C. Phase II study (TAX 326) of docetaxel-cisplatin and docetaxel carboplatin versus vinorelbine-cisplatin for the first-line treatment of advanced/metastatic non-small-cell lung cancer: analysis in elderly patients [abstract 2528]. Proc Am Soc Clin Oncol 2003;22:629
86. Kelly K, Giarritta S, Akerley W, et al. Should patients receive combination chemotherapy for advanced stage non-small cell lung cancer (NSCLC)? An analysis of Southwest Oncology Trials 9509 and 9308 [abstract 1313]. Proc Am Soc Clin Oncol 2001;20:329a
87. Costa GJ, Fernandes AL, Pereira JR, et al. Survival rates and tolerability of platinum-based chemotherapy regimens for elderly patients with non-small-cell lung cancer. Lung Cancer 2008;53:171-176
88. Gridelli C, Maione P, Illiano A, et al. Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P Studies. J Clin Oncol 2007;25:4663-4669
89. Pepe C, Hasan B, Winton TL, et al. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup study JBR.10. J Clin Oncol 2007;25:1553-1561
90. Leong SS, Toh CK, Lim WT, et al. A randomized phase II trial of single-agent gemcitabine, vinorelbine, or docetaxel in patients with advanced non-small cell lung cancer who have poor performance status and/or are elderly. J Thorac Oncol 2007;2:230-236
91. Kudoh S, Takeda K, Nakagawa K, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non small cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 2006;24:3657-3663
92. Douillard JY, Laporte S, Fossela F, et al. Comparison of docetaxel-and Vinca alkaloid-based chemotherapy in the first line treatment of advanced non small cell lung cancer: a meta-anlysis of seven randomized clinical trial. J Thorac Oncol 2007;2:939-946
93. Helbekkmo N, Sundstromn SH, Aasebo U, et al. Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer 2007;97:283-289
94. Gao G, Jiang J, Liang X, et al. A meta-analysis of platinum plus gemcitabine or vinorelbine in the treatment of advanced non-small-cell lung cancer. Lung Cancer 2009; 65:339-344
95. Crinò L, Cappuzzo F, Zatloukal P, et al. Gefitinib versus vinorelbine in chemotherapy-näive elderly patients with advanced non small cell lung cancer (INVITE): a randomized phase II study. J Clin Oncol 2008;26:4253-4260
96. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. J Clin Oncol 2008;26:3552-3559
97. Douillard JY, Tribodet H, His P, et al. Lung Adjuvant Cisplatin Evaluation (LACE vinorelbine project): pooled analysis of adjuvant vinorelbine-cisplatin trials in completely resected non-small-cell lung cancer. Ann Oncol 2006;17(Suppl):231
98. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non small cell lung cancer (FLEX): an open label randomised phase III trial. Lancet 2009;373:1525-1531
99. Lynch TJ, Patel T, Dreisbach L, et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010;28:911-917
100. Fojo T, Grady C. How much is life worth: Cetuximab, non-small-cell lung cancer, and the $440 billion question. J Natl Cancer Inst 2009;101:1044-1048